Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)

BACKGROUND: Apatinib is approved in China for the treatment of advanced gastric adenocarcinoma that had progressed or relapsed after standard systemic chemotherapy treatments. However, the effectiveness of Apatinib under real-world condition has not been evaluated and the drug performance under idea...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yijie, Zhao, Weijie, Sun, Peichun, Deng, Wenying, Deng, Junli, Zong, Hong, Wang, Junsheng, Guo, Yanzhen, Liu, Huaimin, Cang, Shundong, Shang, Ke, Chen, Xiaobing, Wang, Jin, He, Dezhi, Wu, Gang, Zhang, Zhen, Zhang, Liguo, Xu, Feng, Tian, Chuntao, Qiao, Chaofeng, Chen, Gongbin, Zhang, Guifang, Ma, Tianjiang, Gao, Liwei, Zhang, Guozheng, Liu, Jing, Eslick, Guy D., Almhanna, Khaldoun, Lino-Silva, Leonardo S., Aprile, Giuseppe, Li, Ning, Luo, Suxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843423/
https://www.ncbi.nlm.nih.gov/pubmed/36660622
http://dx.doi.org/10.21037/atm-22-5995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843423/
https://www.ncbi.nlm.nih.gov/pubmed/36660622
http://dx.doi.org/10.21037/atm-22-5995

Ejemplares similares